Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBD1016 in Chronic Hepatitis D Virus Infection
NCT06649266Phase 2Active, not recruiting
- Sponsor
- Ribocure Pharmaceuticals AB
- Start
- Aug 2024
- Primary completion
- Sep 2026
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of RBD1016 in chronic hepatitis D (2 arms), sponsored by Ribocure Pharmaceuticals AB. Primary endpoint: Mean change (log10 value) vs. baseline in HDV RNA levels in plasma at 60 weeks. Started Aug 2024; status: active, not recruiting.
02
Drugs
RBD1016
03
Conditions
chronic hepatitis D
Beyond the preview
Go deeper on NCT06649266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649266.